Patents Examined by Michael Szperka
  • Patent number: 10981963
    Abstract: This invention relates to an alpha-1-microglobulin derived protein for medical use.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: April 20, 2021
    Assignee: Guard Therapeutics International AB
    Inventors: Lena Wester Rosenlöf, Anneli Edström Hägerwall, Bo Åkerström
  • Patent number: 10968269
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: April 6, 2021
    Assignee: Agilent Technologies, Inc.
    Inventors: Jørgen Schøller, Liselotte Brix, Henrik Pedersen
  • Patent number: 10961506
    Abstract: This disclosure provides compositions and methods for the activation and expansion of human T cells or NK cells using soluble monospecific antibody complexes.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: March 30, 2021
    Assignee: STEMCELL Technologies Inc.
    Inventor: Andy Isamu Kokaji
  • Patent number: 10954503
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: March 23, 2021
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Uma Sinha, Genmin Lu, Pamela B. Conley
  • Patent number: 10954308
    Abstract: The disclosure generally provides antibodies and antigen binding fragments of antibodies that bind ticagrelor and metabolites of ticagrelor. The disclosure also provides compositions comprising the antibodies, nucleic acid molecules encoding the antibodies, methods of treating a patient comprising administering the antibodies, and methods of making and using the antibodies.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: March 23, 2021
    Assignee: MEDIMMUNE LIMITED
    Inventors: Andrew Buchanan, Sven Nylander, Mark Penney, Philip Newton, Feenagh Keyes, Tord Inghardt
  • Patent number: 10954504
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: March 23, 2021
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • Patent number: 10947298
    Abstract: Described herein dog and cat food additives and compositions comprising secretory IgA.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: March 16, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jordan Marshall Sand, Mark E. Cook, Lisa Ann Krugner-Higby, James Mukasa Ntambi
  • Patent number: 10925962
    Abstract: Provided are: a polymeric IgA-type recombinant antibody; a medicine containing this polymeric IgA-type recombinant antibody as an active ingredient; a method for producing this polymeric IgA type antibody, the method including the step of coexpressing an IgA-type antibody heavy-chain protein, an antibody light-chain protein, an antibody J-chain protein, and a secretory component protein within a single cell; and a method for improving the antigen-binding activity or neutralizing activity of this antibody, the method including the step of making an antibody into a polymeric IgA-type.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: February 23, 2021
    Assignee: Nippi, Incorporated
    Inventors: Shinji Saito, Tadaki Suzuki, Hideki Hasegawa, Akira Ainai, Kiyoko Goto, Tomonori Ueno, Yuki Taga
  • Patent number: 10927362
    Abstract: The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: February 23, 2021
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Joe Salas, Robert T. Peters
  • Patent number: 10927381
    Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as molecules used proteins or peptides, such as LL37.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: February 23, 2021
    Assignee: Base Pair Biotechnologies, Inc.
    Inventors: George W. Jackson, Robert Batchelor, Truong Nguyen, Victoria Singer, Garam Lee, Rafal Drabek
  • Patent number: 10919980
    Abstract: The present invention is based on the finding that administration of polypeptides comprising at least one Immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. The invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) for use in treating a vWF-related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: February 16, 2021
    Assignee: Ablynx N.V.
    Inventor: Christian Duby
  • Patent number: 10907151
    Abstract: The present disclosure provides methods for inhibiting and/or reducing self-reactive IgE and/or basophils, thereby treating or preventing lupus, lupus nephritis, and lupus-related disorders.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 2, 2021
    Assignee: The United States of America, as Represented By The Secretary, Department of Health and Human Services
    Inventors: Juan Rivera, Nicolas Charles
  • Patent number: 10906970
    Abstract: The present invention relates to a method of generation of fully functional heavy chain-only antibodies in transgenic mice in response to antigen challenge.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 2, 2021
    Assignee: Erasmus University Medical Centre
    Inventors: Franklin Gerardus Grosveld, Richard Willhelm Janssens, Dubravka Drabek, Roger Kingdon Craig
  • Patent number: 10898554
    Abstract: The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: January 26, 2021
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Glenn Pierce, Samantha Truex, Robert T. Peters, Haiyan Jiang
  • Patent number: 10881742
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 5, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert T. Peters
  • Patent number: 10882919
    Abstract: The present invention provides an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: January 5, 2021
    Assignee: Rallybio IPA, LLC
    Inventors: Terje Michaelsen, Oistein Ihle, Tor Brynjar Stuge, Anne Husebekk, Heidi Tiller, Mariana Eksteen, Bjorn Ragnar Skogen
  • Patent number: 10875929
    Abstract: The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: December 29, 2020
    Assignee: Pfizer Inc.
    Inventors: Debra Pittman, James R. Apgar, Zong Sean Juo, Macy Jin, Mark Stahl, Gregory J. Carven, Matthew Holsti, Susan Benard, Sunita R. Hett, Reema Jasuja
  • Patent number: 10875924
    Abstract: Antibodies and antibody fragments that specifically bind to glycoprotein IIb/IIIa (GPIIb/IIIa) are disclosed. Chimeric molecules comprising such antibodies or antigen-binding fragments are also disclosed. In addition, methods of using the disclosed antibodies, antibody fragments, and chimeric molecules, e.g., to target agents to platelets and for the treatment or prevention of diseases or disorders are provided.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: December 29, 2020
    Assignee: Biogen MA Inc.
    Inventors: Joe Salas, Karl Hanf, Arjan van der Flier, Bradley R. Pearse
  • Patent number: 10871489
    Abstract: Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: December 22, 2020
    Assignee: Institute of Arthritis Research, LLC
    Inventor: Craig D. Scoville
  • Patent number: 10858445
    Abstract: The present invention is based on the finding that administration of polypeptides comprising at least one Immunoglobulin single variable domains against vWF to human TTP patients provides a significant decrease in the time to response. The invention provides a polypeptide comprising at least one immunoglobulin single variable domain (ISVD) against von Willebrand Factor (vWF) for use in treating a vWF-related disease in a human in need thereof. The invention further relates to dosage unit forms, kits and medical uses for treating TTP.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: December 8, 2020
    Assignee: Ablynx N.V.
    Inventor: Christian Duby